Overview

Secondary Adjuvant Long Term Study With Arimidex

Status:
Completed

Trial end date:
2017-06-30

Target enrollment:

Participant gender:

Summary

The study assesses the effect of further 2 years vs further 5 years of adjuvant treatment with anastrozole after initial 5 years of adjuvant endocrine therapy.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Anastrozole